Tenax Therapeutics (NASDAQ:TENX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

A number of other analysts also recently issued reports on the company. William Blair reissued an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday, March 10th. Leerink Partners set a $20.00 target price on Tenax Therapeutics in a research note on Monday. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Tenax Therapeutics Stock Performance

Shares of TENX stock opened at $6.41 on Thursday. Tenax Therapeutics has a fifty-two week low of $2.77 and a fifty-two week high of $7.89. The stock’s 50-day simple moving average is $6.44 and its 200-day simple moving average is $5.23.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Two Sigma Investments LP acquired a new stake in shares of Tenax Therapeutics during the fourth quarter worth $84,000. Sphera Funds Management LTD. bought a new position in Tenax Therapeutics in the 3rd quarter valued at about $101,000. Geode Capital Management LLC grew its position in Tenax Therapeutics by 32.4% in the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $151,000 after buying an additional 5,964 shares in the last quarter. Millennium Management LLC bought a new position in shares of Tenax Therapeutics during the 4th quarter valued at about $166,000. Finally, Stonepine Capital Management LLC bought a new position in shares of Tenax Therapeutics during the 3rd quarter valued at about $173,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.